CK Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results

from the IV MB, by yyy60:

>>CK Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results

HPB Surgery
Volume 2010 (2010), Article ID 309780, 8 pages
doi:10.1155/2010/309780
Clinical Study

Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results

K. Goyal,1 D. Einstein,2 M. Yao,2 C. Kunos,2 F. Barton,2 D. Singh,3 C. Siegel,1 J. Stulberg,1 and J. Sanabria1

(1) Departments of Surgery, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
(2) Departments of Radiation Oncology, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
(3) Departments of Medicine, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA

Received 24 November 2009; Revised 12 April 2010; Accepted 24 May 2010

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and secondary malignancies of the liver. We report on our updated experience with SBRT in patients with non-resectable tumors of the liver.

METHODS: Our first 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC (n=6), IHC (n=3), and LM (n=8) are presented. Mean radiation dose was 34Gy delivered over 1–3 fractions.

RESULTS: Treated patients had a mean decrease in maximum pretreatment tumor diameter from 6.9±4.6 cm to 5.0±2.1 cm at three months after treatment (P<.05). The mean total tumor volume reduction was 44% at six months (P<.05). 82% of all patients (14/17) achieved local control with a median follow-up of 8 months. 100% of patients with HCC (n=6) achieved local control. Patients with surgically placed fiducial markers had no complications related to marker placement.

CONCLUSION: Our preliminary results showed that SBRT is a safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events. Further studies are needed to define its role in the management of these malignancies.


** Click the link for full detail